

MANAGEMENT TEAM

Ethan Mann, PhD, MBA

CEO

15 years in infectious disease, 7 years in start-ups, previous exit

Steven Dow, PhD, DVM

Professor of Immunology

Founder & CTO

Serial inventor and entrepreneur

Kirstin Liechty

Head of Product Development

20 years in cell therapies and global clinical trial management

Grant Baesman, MBA

CFO

20 years in financial management and bioscience start-ups

MARKET

Infectious disease specialists, orthopedic revision surgery prevention, resistant infections

FINANCIAL INFORMATION

Stage: Pre-seed

Previous Capital: \$320,000

Seeking: \$2.5 M Equity

USE OF PROCEEDS

IND-enabling work

FDA IND Approval

I have nineteen patients with chronic infections today, if this was available now, I'd give it to every one of them!

- Dr. Laura Damioli, Assistant Professor of Medicine, Infectious Disease, Univ. of CO Anschutz Medical Campus

Validus Cellular Therapeutics

For patients and doctors battling chronic resistant infections, Validus Cellular Therapeutics is developing VuropacinCT, a novel preclinical stage anti-infective therapy unlike current small molecule antibiotics which are susceptible to resistance and are limited accessing infections. VuropacinCT is a cell therapy to be given with standard of care antibiotic regimens to successfully treat of chronic infections.

A Novel Approach to Infections

Infections are difficult to treat for many reasons, frequently due to genetically resistant bacteria or a deep-seated nature. Validus is commercializing a proprietary activation process making mesenchymal stem cells capable of healing these resistant infections. Activated stem cells have been shown to both boost the natural immune system and directly kill bacteria.

Infected Paw



Healed Paw



Compelling Investment Highlights

- Experienced team
- Quick to first-in-human studies (12 mon)
- Billion-dollar resistant infection market
- Early exit opportunity
- Strong pricing power capacity
- Broad therapeutic efficacy
- Unique competitive position
- Defined regulatory path with accelerated opportunities
- Safe cell therapy approach
- Clear value-generating growth milestones
- Clear strategic milestones